Cytoglobin as a Prognostic Factor for Pancreatic Ductal Adenocarcinoma

Pancreas ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Hiroshi Kono ◽  
Naohiro Hosomura ◽  
Hidetake Amemiya ◽  
Hiromichi Kawaida ◽  
Shinji Furuya ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma

scholarly journals MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor

2019 ◽  
Vol 18 ◽  
pp. 153303381882431 ◽  
Author(s):  
Yan Chen ◽  
Huiyun Zhu ◽  
Yuqiong Wang ◽  
Yingxiao Song ◽  
Pingping Zhang ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Protein Kinase ◽  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Cell Lines ◽  
Mitogen Activated Protein Kinase ◽  
Ductal Adenocarcinoma ◽  
Adenocarcinoma Cell ◽  
Nuclear Transcription Factor ◽  
Mitogen Activated Protein

The role of microRNA-132 in human pancreatic ductal adenocarcinomas is still ambiguous. We explored the association between microRNA-132 and pancreatic ductal adenocarcinoma prognosis. The expression of microRNA-132 in 50 pancreatic ductal adenocarcinoma tissue samples and pancreatic ductal adenocarcinoma cell lines was examined, and the association between its expression and pancreatic ductal adenocarcinoma prognosis was assessed. Functional analysis and factors downstream of microRNA-132 were investigated. Kaplan-Meier survival curves showed that high expression of microRNA-132 was a significant prognostic factor for 1-year survival of patients with pancreatic ductal adenocarcinoma ( P = .028). Multivariate analysis for overall survival indicated that high expression of microRNA-132 was an independent prognostic factor for patients with pancreatic ductal adenocarcinoma ( P = .044). Low expression of microRNA-132 was associated with poor prognosis in pancreatic ductal adenocarcinoma. Ectopic expression of microRNA-132 significantly inhibited proliferation and promoted apoptosis of 2 pancreatic ductal adenocarcinoma cell lines. Bioinformatic analysis revealed that microRNA-132 may exert its effects on pancreatic ductal adenocarcinoma through downregulating mitogen-activated protein kinase 3 and nuclear transcription factor Y subunit α. The results of this study further our understanding of the relationship between microRNA-132 and pancreatic ductal adenocarcinoma by showing that microRNA-132 might inhibit the progression of pancreatic ductal adenocarcinoma by regulating mitogen-activated protein kinase and nuclear transcription factor Y subunit alpha.

Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma

2019 ◽  
Vol 476 (4) ◽  
pp. 561-568 ◽  
Author(s):  
Ekaterina Petrova ◽  
Verena Zielinski ◽  
Louisa Bolm ◽  
Cleopatra Schreiber ◽  
Juliana Knief ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Budding ◽  
Ductal Adenocarcinoma

Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma

2017 ◽  
Vol 24 (8) ◽  
pp. 2379-2386 ◽  
Author(s):  
Marco Dal Molin ◽  
Amanda L. Blackford ◽  
Abdulrehman Siddiqui ◽  
Aaron Brant ◽  
Christy Cho ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Independent Prognostic Factor ◽  
Ductal Adenocarcinoma

scholarly journals High Periostin Expression is an Independent Positive Prognostic Factor in Pancreatic Ductal Adenocarcinoma

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e764
Author(s):  
I. Budeyri ◽  
S. Goklemez ◽  
Z. Pan ◽  
S. Hausmann ◽  
C.W. Michalski ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Ductal Adenocarcinoma

Tumor Budding Is an Independent Adverse Prognostic Factor in Pancreatic Ductal Adenocarcinoma

2015 ◽  
Vol 39 (4) ◽  
pp. 472-478 ◽  
Author(s):  
Kate O’Connor ◽  
Hector H. Li-Chang ◽  
Steven E. Kalloger ◽  
Renata D. Peixoto ◽  
Douglas L. Webber ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Budding ◽  
Ductal Adenocarcinoma ◽  
Adverse Prognostic Factor ◽  
Independent Adverse Prognostic Factor

scholarly journals Significance of Frailty in Prognosis After Surgery in Patients with Pancreatic Ductal Adenocarcinoma

2020 ◽  
Author(s):  
Shinichiro Yamada ◽  
Mitsuo Shimada ◽  
Yuji Morine ◽  
Satoru Imura ◽  
Tetsuya Ikemoto ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Pancreatic Resection ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Disease Free Survival ◽  
Ductal Adenocarcinoma ◽  
Albumin Concentration ◽  
Tumor Diameter ◽  
Neutrophil Lymphocyte Ratio

Abstract Background: Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection.Methods: One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ≥4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between two groups. Results: The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil–lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival.Conclusions: Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection.

Sign in / Sign up

Export Citation Format

Share Document